Table 1 Patients’ characteristics and survival times according to clinicopathological factors

a: All patients

Sex

Male

431

75.7

66.0

60.8

52.6

0.637

Female

138

24.3

66.0

57.0

52.7

Localization

AEG

351

61.7

74.2

60.4

52.4

0.81

UICC 7th edition

Gastric cancer

212

37.3

62.2

58.7

52.3

Localization

AEG I

143

25.1

108.0

63.0

55.5

0.288

UICC 6th edition

AEG II/III + GC

426

74.9

64.1

58.9

51.8

Laurén

intestinal

320

56.2

78.8

65.1

57.2

0.029

non-intestinal

234

41.1

47.1

54.8

48.2

Grading

low grade

166

29.2

108.0

69.3

64.7

0.012

high grade

395

69.4

54.1

56.4

47.8

pT

pT0

38

6.7

n.r.

85.6

76.4

<0.001

pT1

52

9.1

n.r.

83.5

83.5

pT2

276

48.5

85.6

68.7

62.5

pT3

184

32.2

26.7

37.4

25.4

pT4

19

3.3

14.2

5.3

0.0

pN

pN0

242

42.5

101.9

76.8

69.6

<0.001

pN1

201

35.3

33.3

48.2

39.4

pN2

74

13

26.3

41.3

34.6

pN3

28

4.9

18.9

25.4

25.4

pNx

24

4.2

n.r.

78.5

78.5

pM

pM0

525

92.3

72.8

62.0

54.6

0.001

pM1

44

7.7

23.6

36.3

32.2

R

R0

476

83.7

74.2

64.7

56.7

<0.001

R1/R2

93

16.3

20.3

34.2

32.2

Neoadjuvant chemotherapy

yes

369

64.9

74.2

61.5

52.6

0.157

no

200

35.1

62.2

56.8

53.1

Characteristics

n

%

Median (months)

3-Y-S (%)

5-Y-S (%)

p

b: Neoadjuvantly treated patients

Sex

Male

309

83.7

78.8

63.2

53.7

0.253

Female

60

16.3

48.6

53.0

46.9

Localization

AEG

287

77.8

78.8

63.4

54.4

0.259

UICC 7th edition

Gastric cancer

82

22.2

42.5

55.7

46.3

Localization

AEG I

139

37.7

108.0

62.8

55.3

0.653

UICC 6th edition

AEG II/III + GC

230

62.3

66.0

61.0

51.1

Laurén

Intestinal

220

59.6

108.0

67.3

58.7

0.014

Non-intestinal

140

37.9

40.5

54.4

44.6

Grading

Low grade

109

29.5

108.0

73.0

68.2

0.008

High grade

254

68.8

47.1

56.8

45.3

pT

pT0

38

10.3

n.r.

85.6

76.4

<0.001

pT1

35

9.5

n.r.

83.2

83.2

pT2

169

45.8

101.9

68.7

60.3

pT3

116

31.4

26.9

39.5

25.2

pT4

11

3.0

14.2

0.0

0.0

pN

pN0

157

42.5

108.0

77.4

69.3

<0.001

pN1

142

38.5

34.0

49.0

38.6

pN2

39

10.6

29.1

44.1

31.6

pN3

17

4.6

18.9

38.5

38.5

pNx

14

3.8

n.r.

77.9

77.9

pM

pM0

328

88.9

82.7

65.1

55.6

<0.001

pM1

41

11.1

23.6

33.4

28.6

R

R0

291

78.9

n.r.

69.0

58.4

<0.001

R1/R2

78

21.1

20.3

32.7

30.4

Clinical response

Responder

105

28.5

39.2

82.6

74.2

<0.001

Nonresponder

263

71.3

108.0

52.4

42.8

TRG

1a,1b

104

28.2

n.r.

83.8

77.4

<0.001

2,3

263

71.3

39.2

52.5

42.1

Characteristics

n

%

Median (months)

3-Y-S (%)

5-Y-S (%)

p

c: Primarily resected patients

Sex

Male

122

61.0

62.2

54.6

50.1

0.318

Female

78

39.0

66.0

60.5

57.5

Localization

AEG

64

32.0

32.6

46.9

44.3

0.049

UICC 7th edition

Gastric cancer

131

65.5

64.1

60.7

56.4

Localization

AEG I

4

2.0

n.r.

75.0

75.0

0.619

UICC 6th edition

AEG II/III + GC

196

98.0

62.2

56.5

52.9

Laurén

Intestinal

100

50.0

62.2

59.8

53.4

0.807

Non-intestinal

94

47.0

64.1

55.7

54.0

Grading

Low grade

57

28.5

62.2

61.5

55.9

0.526

High grade

141

70.5

64.1

55.8

52.2

pT

pT0

0

0.0

<0.001

pT1

17

8.5

n.r.

86.5

86.5

pT2

107

53.5

85.6

68.5

65.4

pT3

68

34.0

25.8

33.2

26.6

pT4

8

4.0

10.3

12.5

12.5

pN

pN0

85

42.5

85.6

76.0

70.2

<0.001

pN1

59

29.5

32.0

45.4

41.6

pN2

35

17.5

21.7

37.9

28.4

pN3

11

5.5

16.1

9.1

9.1

pNx

10

5.0

n.r.

78.8

78.8

pM

pM0

197

98.5

62.2

56.6

52.9

0.684

pM1

3

1.5

n.r.

66.7

66.7

R

R0

185

92.5

64.1

57.8

53.9

0.144

R1/R2

15

7.5

18.1

44.4

0.0